|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.0750 - 0.0750|
|52 Week Range||0.0650 - 0.2250|
|Beta (3Y Monthly)||3.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SYDNEY and HAYWARD, Calif. , Dec. 21, 2018 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) (the "Company"), a clinical-stage biotechnology company developing novel genetic medicines ...
The direct benefit for Benitec Biopharma Limited (ASX:BLT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
SYDNEY , Sept. 19, 2018 /PRNewswire/ -- Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a clinical-stage biotechnology company developing ...
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
Axovant and Benitec Biopharma Rise on Gene Therapy Licensing DealAxovant and Benitec Biopharma enter into a licensing deal
Shares of the biopharmaceutical company rose 5% in early morning trading Monday after it announced it had bought the rights to a new gene therapy treatment designed for a rare form of muscular dystrophy from Benitec Biopharma Ltd. Axovant rose 12 cents -- or 5% -- to $2.68 a share on news of the deal while Benitec skyrocketed $1.52 -- or 67.8% --$3.76. The two companies also entered into a research collaboration to develop five more treatments meant to target neurological disorders.
- Benitec to receive upfront cash payment of US$10 million with additional cash payments totalling US$17.5 million (a total of US$27.5M ) upon completion of near-term milestones for BB-301, now named AXO-AAV-OPMD ...
NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy with its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today reported its consolidated financial results for the 2018 fiscal third quarter to 31 March 2018 (3Q FY18), and highlighted recent progress advancing its pipeline.
SYDNEY , May 15, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) today announced that data from its oculopharyngeal muscular dystrophy (OPMD) program will be presented ...
- Details on the Company's OPMD program and roadmap to be presented by Benitec Management Team - Discussion on disease and market to be presented by internationally renowned key opinion leader Bernard ...
NASDAQ: BNTCW) today provided an update on its two lead programs in head and neck squamous cell carcinoma (HNSCC) and oculopharyngeal muscular dystrophy (OPMD). This update should be read in conjunction with the latest corporate presentation which can be found on the Company's website. The first clinical site has now been opened in Australia and the Company anticipates having additional Australian sites open later this month. Regulatory review with the Ministry of Health is ongoing in Russia and the Company expects approval at the end of May.
NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy and its patented gene-silencing technology named ddRNAi or 'expressed RNAi', today announced the start of its Phase 2 clinical study in Australia with BB-401 as a treatment for patients with head and neck squamous cell carcinoma (HNSCC). The Phase 2 open label study has been designed to explore the safety, tolerability and efficacy of BB-401 following intratumoral injections into the lesions of patients with recurrent or metastatic HNSCC. The study will enrol up to 30 patients at 5-8 sites across Australia and Russia. The trial is registered on www.clinicaltrials.gov with the identifier: NCT03433027, where more details can be found.
SYDNEY , Feb. 22, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative ...
SYDNEY , Jan. 23, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that it has received a $4,112,058 cash refund for the year ended 2017 under the Federal ...